20-Week Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 210 participants.

Also called NCT01906489

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 210 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01906489
Other papers using this trial's data
  • Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease Kidney international, 2016-11 DOI, PubMed 27650732

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01906489. Randomized; quadruple masking; primary purpose treatment. Start 2013-07-23 (actual); primary completion 2014-09-03 (actual). Results posted on 2022-07-01.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
20-Week Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia
Condition
Anemia
Intervention (Drug)
AKB-6548
Intervention (Drug)
Placebo
Lead sponsor
Akebia Therapeutics (class: industry)

Record details

Record id
cardio:ct-nct01906489
Content hash
8002802e14a14eab3f705b33944f681ba820d520302ebc35c1a5b13d5e7abca8